Ozempic, Wegovy, and Mounjaro are all injectable medications used for type 2 diabetes management and/or weight loss. All three belong to the GLP-1 receptor agonist class — medications that mimic a naturally occurring hormone called glucagon-like peptide-1 (GLP-1). Despite this shared mechanism, each drug has a distinct active ingredient, Health Canada-approved indication, dosing regimen, and coverage status in Ontario.
If you or your prescriber are deciding between these medications — or if you are trying to understand what is covered by your drug plan — this guide gives you a clear, evidence-based comparison. Peel Best Pharmacy in Mississauga stocks all three formulations and can counsel you on your options.
What Are GLP-1 Receptor Agonists?
GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in the gut after eating. It signals the pancreas to release insulin in response to rising blood sugar, suppresses glucagon (which would otherwise raise blood sugar), slows how quickly the stomach empties, and sends satiety signals to the brain — reducing appetite.
GLP-1 receptor agonists are drugs that mimic this hormone. By activating GLP-1 receptors, they produce all of the above effects in a sustained, controlled way. The result is improved blood sugar control in type 2 diabetes and, through reduced appetite and slower gastric emptying, meaningful weight loss.
Ozempic and Wegovy use semaglutide — a synthetic GLP-1 analogue. Mounjaro uses tirzepatide, which activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors, making it a dual agonist. This additional GIP action appears to produce greater weight loss than single GLP-1 agonism alone.
Ozempic vs Wegovy vs Mounjaro — Quick Comparison
| Feature | Ozempic | Wegovy | Mounjaro |
|---|---|---|---|
| Active drug | Semaglutide | Semaglutide | Tirzepatide |
| Mechanism | GLP-1 agonist | GLP-1 agonist | GLP-1 + GIP dual agonist |
| Health Canada approved for | Type 2 diabetes | Weight loss (obesity, BMI ≥30 or ≥27 with comorbidity) | Type 2 diabetes (Zepbound for weight loss not yet approved in Canada) |
| Dose range | 0.25–2 mg weekly | 0.25–2.4 mg weekly | 2.5–15 mg weekly |
| Average weight loss | ~10–15% body weight | ~15–18% body weight | ~20–22% body weight |
| Canada availability | Yes (supply improved) | Limited supply | Yes (Mounjaro brand) |
| ODB coverage | Yes — with T2DM criteria via EAP | Not listed on ODB formulary | Limited — check with pharmacist |
| Injection frequency | Once weekly | Once weekly | Once weekly |
| Approximate monthly cost (OOP) | $250–$350/month | $400–$600/month | $300–$450/month |
Prices are approximate Canadian cash-pay estimates as of 2025. Coverage and out-of-pocket costs vary by drug plan. Consult your pharmacist for current pricing.
Ozempic in Canada — Indications and Availability
Ozempic (semaglutide) was approved by Health Canada for the management of type 2 diabetes mellitus in adults. It is prescribed alongside diet and exercise to improve glycemic control, and it has a secondary cardiovascular risk-reduction benefit for patients with established cardiovascular disease.
In practice, Ozempic is also widely prescribed off-label for weight loss in patients without a type 2 diabetes diagnosis. This off-label use drove much of the demand surge that contributed to the 2022–2024 shortages across Canada. Supply has stabilized through 2024 and into 2025, though specific doses may still have intermittent gaps.
For ODB coverage, semaglutide (Ozempic) requires an Exceptional Access Program (EAP) request submitted by your prescriber. Eligibility criteria include a confirmed type 2 diabetes diagnosis with specific A1c thresholds. Many private employer benefit plans cover Ozempic for diabetes with prior authorization; coverage for weight-loss use (off-label) is less consistent and plan-dependent.
Wegovy in Canada — The Weight Loss Indication
Wegovy is the same active ingredient as Ozempic — semaglutide — but formulated and approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia.
Wegovy is dosed at a higher maximum of 2.4 mg weekly (compared to Ozempic's maximum of 2.0 mg for diabetes management), which accounts for its stronger average weight loss outcomes in clinical trials. The STEP program of trials demonstrated average weight loss of approximately 15–18% of body weight over 68 weeks.
Availability in Canada has been limited and inconsistent since Health Canada approval. Most private benefit plans do not cover weight-loss medications, meaning Wegovy is typically an out-of-pocket cost for most Canadian patients — approximately $400 to $600 per month. If you are interested in Wegovy, call Peel Best Pharmacy at (905) 712-0003 to check current stock.
Mounjaro in Canada — Dual Mechanism Advantage
Mounjaro (tirzepatide) is the newest of the three and uses a fundamentally different mechanism. While Ozempic and Wegovy are single GLP-1 receptor agonists, tirzepatide is a dual agonist — it activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously.
This dual action appears to produce significantly greater weight loss than single GLP-1 agonism. The SURMOUNT-1 clinical trial demonstrated average weight loss of approximately 20–22% of body weight with tirzepatide at the maximum 15 mg dose — results that exceed what has been seen with semaglutide in head-to-head comparisons.
In Canada, Mounjaro is currently Health Canada-approved for type 2 diabetes management. Zepbound — the tirzepatide brand specifically indicated for weight loss — has been approved by the FDA in the United States but had not received Health Canada approval as of mid-2025. Prescribers can prescribe Mounjaro off-label for weight loss in patients without type 2 diabetes.
ODB coverage for Mounjaro is limited and requires specific criteria. Call Peel Best Pharmacy at (905) 712-0003 — our pharmacist can review your benefit plan and advise on coverage pathways.
Compounded Semaglutide in Canada — Is It Legal?
Important: Health Canada's position is that compounded semaglutide is not an authorized drug product. Patients should be cautious of online or unregulated sources offering compounded semaglutide without a valid patient-specific prescription from a licensed Canadian prescriber.
Compounding pharmacies in Canada operate under provincial regulation and can compound medications on a patient-specific basis when a licensed prescriber has written a valid prescription. Compounding typically involves creating a custom formulation of an active ingredient — for example, a different concentration, a different delivery vehicle, or a formulation not commercially available.
Health Canada's position is nuanced: while compounding individual patient prescriptions is legal and regulated under provincial pharmacy legislation, compounding copies of brand-name patented products or selling compounded drugs without patient-specific prescriptions is not permitted. The regulatory environment around compounded semaglutide has been evolving, and practices that were tolerated during peak shortages are subject to stricter scrutiny.
Patients should exercise extreme caution with online sources or unlicensed compounding operations offering semaglutide without a prescription. Quality control, sterility, accurate dosing, and ingredient authenticity cannot be assumed from unverified sources.
Peel Best Pharmacy is a licensed compounding pharmacy. For legitimate compounding needs — formulations not commercially available, custom concentrations for specific patient needs, or documented shortage situations with a valid prescription — visit our compounding pharmacy service page or call (905) 712-0003 to speak with our pharmacist.
Which Medication Is Right for You?
The right GLP-1 medication depends on your primary diagnosis, insurance coverage, clinical goals, and tolerance. Only your prescriber can determine what is medically appropriate — but your pharmacist plays an important role in explaining the options, checking coverage, and counselling on side effects.
Type 2 diabetes with ODB or private coverage → Ozempic first
If you have a confirmed type 2 diabetes diagnosis, Ozempic has the strongest coverage pathway via ODB (EAP) and most private plans. It is the established standard of care for GLP-1 therapy in T2DM in Canada.
Weight loss as primary goal with private insurance → discuss Wegovy
If your primary goal is weight loss and you have private insurance that may cover weight management, Wegovy's approved obesity indication gives it a more direct pathway than off-label Ozempic. Coverage is inconsistent — confirm with your insurer first.
Best weight loss outcomes + type 2 diabetes → Mounjaro
Mounjaro produces the highest average weight loss in clinical trials, with dual GLP-1/GIP action. If you have T2DM and want maximum glycemic and weight benefit, tirzepatide may be the better option — discuss with your prescriber.
Supply issues or cost concerns → ask about alternatives
If your prescribed GLP-1 is out of stock or unaffordable, your pharmacist can discuss alternatives including Rybelsus (oral semaglutide), dose adjustments, or coverage assistance programs. Call (905) 712-0003 for current availability.
Drug Coverage in Ontario — ODB, Private Plans, and Out-of-Pocket
Drug coverage for GLP-1 medications in Ontario varies significantly depending on your benefit plan, diagnosis, and the specific medication. Here is a practical overview:
| Drug | ODB (Ontario Drug Benefit) | Private Insurance | Cash Pay Est. |
|---|---|---|---|
| Ozempic (semaglutide) | Yes — via EAP for T2DM with criteria | Most plans cover with PA for T2DM | $250–$350/mo |
| Wegovy (semaglutide) | Not listed on ODB formulary | Rarely covered; plan-dependent | $400–$600/mo |
| Mounjaro (tirzepatide) | Limited — check eligibility | Varies; growing coverage for T2DM | $300–$450/mo |
| Rybelsus (oral semaglutide) | Yes — via EAP for T2DM with criteria | Covered with PA for T2DM | $200–$300/mo |
PA = prior authorization. EAP = Exceptional Access Program. Coverage estimates are approximate as of 2025 and subject to change. Your pharmacist at Peel Best Pharmacy can review your specific benefit plan, submit prior authorization requests on your behalf, and help you navigate manufacturer patient support programs that may reduce out-of-pocket costs.